[{"orgOrder":0,"company":"Corsair Pharma","sponsor":"Junson Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Treprostinil Prodrug","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsair Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Transdermal Patch","sponsorNew":"Corsair Pharma \/ Junson Capital","highestDevelopmentStatusID":"6","companyTruncated":"Corsair Pharma \/ Junson Capital"},{"orgOrder":0,"company":"Corsair Pharma","sponsor":"InstantGMP","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Treprostinil Prodrug","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsair Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corsair Pharma \/ InstantGMP","highestDevelopmentStatusID":"6","companyTruncated":"Corsair Pharma \/ InstantGMP"},{"orgOrder":0,"company":"Corsair Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Corsair Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corsair Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Corsair Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Corsair Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : TRX-248 transdermal system, a once-daily transdermal patch delivering treprostinil, a prostaglandin mimetic, for the treatment of Pulmonary Arterial Hypertension (PAH).

                          Product Name : TRX-248

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : Treprostinil Sodium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : The partmership aims to create improved treatment options for patients with complex medical needs, including PAH treatment with its first product candidate CO-254, a prodrug of treprostinil.

                          Product Name : CO-254

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 28, 2025

                          Lead Product(s) : Treprostinil Prodrug

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : InstantGMP

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : The proceeds will support the clinical advancement of Corsair’s lead product candidate, a prodrug of treprostinil delivered in a proprietary transdermal patch to treat Pulmonary Arterial Hypertension (PAH).

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 20, 2023

                          Lead Product(s) : Treprostinil Prodrug

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Junson Capital

                          Deal Size : $23.0 million

                          Deal Type : Series B Financing

                          blank